|Positive WB detected in||HEK-293T cells, HeLa cells, K-562 cells, MCF-7 cells|
|Positive IP detected in||HEK-293T cells|
|Positive IHC detected in||human kidney tissue|
Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0
|Positive FC detected in||HEK-293T cells|
|Western Blot (WB)||WB : 1:1000-1:6000|
|Immunoprecipitation (IP)||IP : 0.5-4.0 ug for IP and 1:500-1:1000 for WB|
|Immunohistochemistry (IHC)||IHC : 1:100-1:400|
|Sample-dependent, check data in validation data gallery|
The immunogen of 25887-1-AP is Chk1 Fusion Protein expressed in E. coli.
|Host / Isotype||Rabbit / IgG|
|Immunogen||Chk1 fusion protein Ag22993|
|Full Name||CHK1 checkpoint homolog (S. pombe)|
|Calculated molecular weight||54 kDa|
|Observed molecular weight||55 kDa|
|GenBank accession number||BC004202|
|Gene ID (NCBI)||1111|
|Purification Method||Antigen affinity purification|
|Storage Buffer||PBS with 0.02% sodium azide and 50% glycerol pH 7.3.|
|Storage Conditions||Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage.|
CHEK1(Checkpoint kinase-1) is also named as CHK1 and belongs to the protein kinase superfamily. It is implicated in a circuit in which it activates checkpoints, DNA repair and proliferating cell nuclear antigen and FANCD2 monoubiquitinylation(PMID:21389083). CHEK1 protects vertebrate cells against spontaneous chromosome missegregation and is required to sustain anaphase delay when spindle function is disrupted by taxol(PMID:17276342). It has 3 isoforms produced by alternative splicing with the molecular mass of 54 kDa, 44 kDa and 50 kDa.
|Product Specific Protocols|
|WB protocol for Chk1 antibody 25887-1-AP||Download protocol|
|IHC protocol for Chk1 antibody 25887-1-AP||Download protocol|
|IP protocol for Chk1 antibody 25887-1-AP||Download protocol|
|FC protocol for Chk1 antibody 25887-1-AP||Download protocol|
|Click here to view our Standard Protocols|
J Exp Clin Cancer Res
UBE2T-regulated H2AX monoubiquitination induces hepatocellular carcinoma radioresistance by facilitating CHK1 activation.
MAP4K1 functions as a tumor promotor and drug mediator for AML via modulation of DNA damage/repair system and MAPK pathway.
The HDAC and PI3K dual inhibitor CUDC-907 synergistically enhances the antileukemic activity of venetoclax in preclinical models of acute myeloid leukemia.
Clin Cancer Res
RNF126 as a biomarker of a poor prognosis in invasive breast cancer and CHK1 inhibitor efficacy in breast cancer cells.